Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03136679 · ClinicalTrials.gov registry record
Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease
A clinical trial, sponsored by Baylor Research Institute.
- Completed
- Registry status
- 95
- Enrollment target
NCT03136679 is a clinical trial that has completed, run by Baylor Research Institute. The registered enrollment target is 95 participants.
The verdict
NCT03136679 has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- 95 participants
- Enrollment target
Study Summary
This study will perform a targeted metabolic analysis in blood and urine samples from subjects attending the Baylor AT\&T Memory Center. The aim is to identify novel biomarkers that can distinguish normal aging subjects with no cognitive impairment from those with mild, moderate or severe cognitive impairment associated with Alzheimer's disease. Subjects will also be screened for B-vitamin deficiencies that may correlate with other metabolic biomarkers and Alzheimer's disease.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2011-03-22 |
| Est. Completion | 2021-11-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03136679
The ClinicalTrials.gov registry entry for NCT03136679 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03136679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03136679 about?
NCT03136679 is a clinical study titled "Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease". This study will perform a targeted metabolic analysis in blood and urine samples from subjects attending the Baylor AT\&T Memory Center. The aim is to identify novel biomarkers that can distinguish normal aging subjects with no cognitive impairment from those with mild, moderate or severe cognitive ...
What is the current status of trial NCT03136679?
This trial is currently completed. The enrollment target is 95 participants. The study started on 2011-03-22. Estimated completion is 2021-11-24.
Who is sponsoring clinical trial NCT03136679?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.